Zhui Chen

605 total citations
20 papers, 339 citations indexed

About

Zhui Chen is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Zhui Chen has authored 20 papers receiving a total of 339 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Molecular Biology, 6 papers in Immunology and 5 papers in Oncology. Recurrent topics in Zhui Chen's work include Immune cells in cancer (5 papers), Fibroblast Growth Factor Research (4 papers) and Cancer, Hypoxia, and Metabolism (3 papers). Zhui Chen is often cited by papers focused on Immune cells in cancer (5 papers), Fibroblast Growth Factor Research (4 papers) and Cancer, Hypoxia, and Metabolism (3 papers). Zhui Chen collaborates with scholars based in United States, China and Switzerland. Zhui Chen's co-authors include Patrick J. Casey, Yì Wáng, James Otto, Martin O. Bergö, Stephen G. Young, Yiyu Cheng, Yufeng Zhang, Yi Tao, Carolyn Weinbaum and Ronald L. Johnson and has published in prestigious journals such as Journal of Biological Chemistry, PLoS ONE and Cancer Research.

In The Last Decade

Zhui Chen

19 papers receiving 332 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Zhui Chen United States 8 241 61 30 30 27 20 339
Ansu Kumar United States 10 231 1.0× 75 1.2× 15 0.5× 29 1.0× 26 1.0× 24 360
Aide Negri Italy 8 184 0.8× 87 1.4× 28 0.9× 16 0.5× 24 0.9× 8 393
Tiziana Tataranni Italy 8 228 0.9× 51 0.8× 18 0.6× 20 0.7× 14 0.5× 8 383
Joo‐Yun Byun South Korea 8 228 0.9× 56 0.9× 36 1.2× 23 0.8× 31 1.1× 29 365
Alessio Malacrida Italy 11 263 1.1× 66 1.1× 11 0.4× 25 0.8× 26 1.0× 25 390
Jiajun Yap Singapore 7 329 1.4× 101 1.7× 28 0.9× 16 0.5× 18 0.7× 11 477
Aloran Mazumder South Korea 13 279 1.2× 96 1.6× 34 1.1× 14 0.5× 18 0.7× 25 435
Rohini Gomathinayagam United States 11 286 1.2× 41 0.7× 26 0.9× 28 0.9× 12 0.4× 17 459
Siwei Li China 13 403 1.7× 90 1.5× 26 0.9× 19 0.6× 10 0.4× 25 556

Countries citing papers authored by Zhui Chen

Since Specialization
Citations

This map shows the geographic impact of Zhui Chen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Zhui Chen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Zhui Chen more than expected).

Fields of papers citing papers by Zhui Chen

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Zhui Chen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Zhui Chen. The network helps show where Zhui Chen may publish in the future.

Co-authorship network of co-authors of Zhui Chen

This figure shows the co-authorship network connecting the top 25 collaborators of Zhui Chen. A scholar is included among the top collaborators of Zhui Chen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Zhui Chen. Zhui Chen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Cheng, Dai, Bin Shen, Shenyan Liu, et al.. (2025). Pharmacologic inhibition of CSF-1R suppresses intrinsic tumor cell growth in osteosarcoma with CSF-1R overexpression. Journal of Translational Medicine. 23(1). 900–900.
2.
Shen, Bin, et al.. (2025). Abstract LB427: The MTA-cooperative PRMT5 inhibitor ABSK131 exhibits potent activity and broad synergistic potential in MTAP-deleted cancer models. Cancer Research. 85(8_Supplement_2). LB427–LB427. 1 indexed citations
3.
Zhang, Nannan, Bin Shen, Dai Cheng, et al.. (2024). Abstract 1228: Selective FGFR4 inhibitor Irpagratinib (ABSK011) exhibits broad synergistic and combinatory anti-tumor effects with other therapeutic agents in preclinical HCC models. Cancer Research. 84(6_Supplement). 1228–1228. 1 indexed citations
4.
Zhu, Zhixuan, Shenyan Liu, Yongxian Zhang, et al.. (2023). EGFR Inhibition Overcomes Resistance to FGFR4 Inhibition and Potentiates FGFR4 Inhibitor Therapy in Hepatocellular Carcinoma. Molecular Cancer Therapeutics. 22(12). 1479–1492. 7 indexed citations
5.
Chen, Zhui, et al.. (2023). TCGA RNA-Seq and Tumor-Infiltrating Lymphocyte Imaging Data Reveal Cold Tumor Signatures of Invasive Ductal Carcinomas and Estrogen Receptor-Positive Human Breast Tumors. International Journal of Molecular Sciences. 24(11). 9355–9355. 7 indexed citations
6.
Ying, Haiyan, et al.. (2023). Abstract LB316: A next-generation KRASG12C inhibitor ABSK071 demonstrated broad synergy with other therapeutic agents in KRASG12C mutated cancer models. Cancer Research. 83(8_Supplement). LB316–LB316. 1 indexed citations
7.
Zhang, Nannan, Dai Cheng, Jiacheng Zhang, et al.. (2023). Abstract LB329: A potent and selective small molecule inhibitor of CSF-1R ABSK021 demonstrates strong efficacy in preclinical models of osteosarcoma. Cancer Research. 83(8_Supplement). LB329–LB329. 1 indexed citations
8.
Zhang, Nannan, Zhui Chen, Bin Shen, et al.. (2022). 985 Inhibition of fibroblast growth factor receptor 4 (FGFR4) signaling activates tumor interferon (IFN) signaling in hepatocellular carcinoma (HCC). Regular and Young Investigator Award Abstracts. A1027–A1027. 1 indexed citations
9.
Zhu, Zhixuan, et al.. (2022). 1441 A potent and selective small molecule antagonist of CD73 ABSK051 reverses immunosuppression through reduction of adenosine production. Regular and Young Investigator Award Abstracts. A1498–A1498. 1 indexed citations
10.
Zhao, Baowei, Mingming Zhang, Yuan Zhao, et al.. (2018). Abstract LB-288: A highly selective small molecule CSF-1R inhibitor demonstrates strong immunomodulatory activity in syngeneic models. Cancer Research. 78(13_Supplement). LB–288. 3 indexed citations
11.
Chen, Zhui. (2018). Abstract LB-272: Discovery and characterization of a novel FGFR4 Inhibitor for the treatment of hepatocellular carcinoma. Cancer Research. 78(13_Supplement). LB–272. 2 indexed citations
12.
Kim, Jeesun, Ruipeng Zhang, Xiaoqin Yang, et al.. (2016). Histone Demethylase LSD1 Promotes Adipocyte Differentiation through Repressing Wnt Signaling. Cell chemical biology. 23(10). 1228–1240. 40 indexed citations
13.
14.
15.
Guo, Jun, Lisa Roberts, Zhui Chen, et al.. (2015). JAK2V617F Drives Mcl-1 Expression and Sensitizes Hematologic Cell Lines to Dual Inhibition of JAK2 and Bcl-xL. PLoS ONE. 10(3). e0114363–e0114363. 27 indexed citations
16.
Tao, Yi, Zhui Chen, Yufeng Zhang, Yì Wáng, & Yiyu Cheng. (2013). Immobilized magnetic beads based multi-target affinity selection coupled with high performance liquid chromatography–mass spectrometry for screening anti-diabetic compounds from a Chinese medicine “Tang-Zhi-Qing”. Journal of Pharmaceutical and Biomedical Analysis. 78-79. 190–201. 54 indexed citations
17.
18.
Chen, Zhui & Melanie H. Cobb. (2006). Activation of MEKK1 by Rho GTPases. Methods in enzymology on CD-ROM/Methods in enzymology. 406. 468–478. 5 indexed citations
19.
Fiordalisi, James J., Ronald L. Johnson, Carolyn Weinbaum, et al.. (2003). High Affinity for Farnesyltransferase and Alternative Prenylation Contribute Individually to K-Ras4B Resistance to Farnesyltransferase Inhibitors. Journal of Biological Chemistry. 278(43). 41718–41727. 73 indexed citations
20.
Chen, Zhui, James Otto, Martin O. Bergö, Stephen G. Young, & Patrick J. Casey. (2000). The C-terminal Polylysine Region and Methylation of K-Ras Are Critical for the Interaction between K-Ras and Microtubules. Journal of Biological Chemistry. 275(52). 41251–41257. 81 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Ansu Kumar Breakdown of academic impact, for papers by Aide Negri Breakdown of academic impact, for papers by Tiziana Tataranni Breakdown of academic impact, for papers by Joo‐Yun Byun Breakdown of academic impact, for papers by Alessio Malacrida Breakdown of academic impact, for papers by Jiajun Yap Breakdown of academic impact, for papers by Aloran Mazumder Breakdown of academic impact, for papers by Rohini Gomathinayagam Breakdown of academic impact, for papers by Siwei Li
Rankless by CCL
2026